Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 4, 2015, Pages 353-360

  Jeewandara, Thamarasee M ^a,b   Ameer, Omar Z ^a   Boyd, Rochelle ^a   Wyse, Benjamin F ^a   Underwood, Conor F ^a   Phillips, Jacqueline K ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aldosterone; Fibrosis; Hypertension; Left ventricular hypertrophy; Polycystic kidney disease; Vascular

Indexed keywords

ACETYLCHOLINE; ACTIN; ALDOSTERONE ANTAGONIST; ALPHA CARDIAC ACTIN; BRAIN NATRIURETIC PEPTIDE; CREATININE; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; NORADRENALIN; PLASMA PROTEIN; SERUM ALBUMIN; SERUM GLOBULIN; SPIRONOLACTONE; UNCLASSIFIED DRUG; WATER; BIOLOGICAL MARKER; MINERALOCORTICOID ANTAGONIST;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FLUID INTAKE; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HYPERTENSION; KIDNEY CYST; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; LEWIS RAT; LPK RAT; MALE; NONHUMAN; PATHOGENESIS; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; VASCULAR FIBROSIS; ANIMAL; AORTA; BLOOD; BLOOD PRESSURE; CELL PROTECTION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; HEART DISEASES; HEART MUSCLE; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; POLYCYSTIC KIDNEY DISEASES; SEX DIFFERENCE; TIME; URINE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; AORTA; BIOMARKERS; BLOOD PRESSURE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEART DISEASES; HYPERTENSION; KIDNEY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIUM; POLYCYSTIC KIDNEY DISEASES; RATS, INBRED LEW; SEX FACTORS; SPIRONOLACTONE; TIME FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 84925405301     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12372     Document Type: Article

References (37)

1. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 2006; 17: 2985-91.
2. Jain G, Campbell RC, Warnock DG. Mineralocorticoid receptor blockers and chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4: 1685-91.
3. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-17.
4. Ecder T, Schrier RW. Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Expert Rev. Cardiovasc. Ther. 2004; 2: 369-74.
5. Taira M, Toba H, Murakami M et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur. J. Pharmacol. 2008; 589: 264-71.
6. Remuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J. Am. Soc. Nephrol. 2008; 19: 1459-62.
7. Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst. Rev. 2010; 8: CD008169.
8. Briet M, Schiffrin EL. Aldosterone: Effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 2010; 6: 261-73.
9. Wilson PD. Mouse models of polycystic kidney disease. Curr. Top. Dev. Biol. 2008; 84: 311-50.
10. Hildebrandt F, Otto E. Cilia and centrosomes: A unifying pathogenic concept for cystic kidney disease? Nat. Rev. Genet. 2005; 6: 928-40.
11. Harrap SB, Davies DL, Macnicol AM et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int. 1991; 40: 501-8.
12. Chapman AB, Torres VE, Perrone RD et al. The HALT polycystic kidney disease trials: Design and implementation. Clin. J. Am. Soc. Nephrol. 2010; 5: 102-9.
13. McCooke JK, Appels R, Barrero RA et al. A novel mutation causing nephronophthisis in the Lewis polycystic kidney rat localises to a conserved RCC1 domain in Nek8. BMC Genom. 2012; 13: doi:10.1186/147-2164-13-393.
14. Liu S, Lu W, Obara T et al. A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish. Development 2002; 129: 5839-46.
15. Fischer E, Gresch L, Reimann A, Pontoglio M. Cystic kidney diseases: Learning from animal models. Nephrol. Dial. Transplant. 2004; 19: 2700-2.
16. Phillips JK, Hopwood D, Loxley RA et al. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney Blood Press. Res. 2007; 30: 129-44.
17. Ng K, Hildreth CM, Phillips JK, Avolio AP. Aortic stiffness is associated with vascular calcification and remodeling in a chronic kidney disease rat model. Am. J. Physiol. Renal. Physiol. 2011; 300: F1431-6.
18. Hildreth CM, Kandukuri DS, Goodchild AK, Phillips JK. Temporal development of baroreceptor dysfunction in a rodent model of chronic kidney disease. Clin. Exp. Pharmacol. Physiol. 2013; 40: 458-65.
19. Gabow PA, Johnson AM, Kaehny WD et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992; 41: 1311-19.
20. Torres VE, Bengal RJ, Nickander KK, Grande JP, Low PA. Renal concentration of alpha-tocopherol: Dependence on gender and lack of effect on polycystic kidney disease in Han:SPRD rats. Am. J. Kidney Dis. 1998; 31: 687-93.
21. Lager D, Qian Q, Bengal R, Ishibashi M, Torres V. The pck rat: A new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int. 2001; 59: 126-36.
22. Stringer KD, Komers R, Osman SA, Oyama TT, Lindsley JN, Anderson S. Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int. 2005; 68: 1729-39.
23. Campese VM, Bianchi S, Bigazzi R. Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? Curr. Opin. Nephrol. Hypertens. 2000; 9: 143-7.
24. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998; 339: 1448-56.
25. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 2010; 21: 1819-34.
26. Rafiq K, Hitomi H, Nakano D, Nishiyama A. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J. Pharmacol. Sci. 2011; 115: 1-7.
27. Ding A, Kalaignanasundaram P, Ricardo SD et al. Chronic treatment with tempol does not significantly ameliorate renal tissue hypoxia or disease progression in a rodent model of polycystic kidney disease. Clin. Exp. Pharmacol. Physiol. 2012; 39: 917-29.
28. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J. Am. Soc. Nephrol. 2003; 14: 2395-401.
29. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin. J. Am. Soc. Nephrol. 2009; 4 (Suppl. 1): S79-91.
30. Wang X, Oka T, Chow FL et al. Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009; 54: 575-82.
31. Nehme J, Mercier N, Labat C et al. Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: Effect of eplerenone. J. Renin Angiotensin Aldosterone Syst. 2006; 7: 31-9.
32. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 1993; 25: 563-75.
33. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens. Res. 2005; 28: 925-36.
34. Michea L, Villagran A, Urzua A et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 2008; 52: 295-300.
35. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: Effects of eplerenone. Circulation 2002; 106: 2848-53.
36. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease effects on the cardiovascular system. Circulation 2007; 116: 85-97.
37. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8: R19.